# Sickle Cell Disease Treatment Demonstration Program

Source: https://welltoldgrants.com/grants/hrsa-21-032-sickle-cell-disease-treatment-demonstration-program/  
Official notice: https://www.grants.gov/search-results-detail/331673

> Health Resources and Services Administration offered grants to the applicants described in the notice. It expected to make about 5 awards worth $5.0 million in total. Applications closed on May 3, 2021.

| Field | Value |
|---|---|
| Opportunity number | HRSA-21-032 |
| Agency | Health Resources and Services Administration |
| Status | Forecast |
| Deadline | May 3, 2021 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 5 |
| Total funding | $5.0 million |
| Cost sharing | not required |
| Assistance Listings | 93.365 |

## Who can apply

- Others (see text field entitled "Additional Information on Eligibility" for clarification)

Eligible applicants include a Federally-qualified health center, a nonprofit hospital or clinic, or a university health center that provides primary health care, that has a collaborative agreement with a community-based sickle cell disease organization or a nonprofit entity with experience in working with individuals who have sickle cell disease; and demonstrates to the HRSA Administrator that either the federally-qualified health center, the nonprofit hospital or clinic, the university health center, the organization or entity described in clause (i) 42 USC § 300b-5, or experts as described in paragraph (2)(C) of 42 USC § 300b-5, has at least five (5) years of experience in working with individuals who have sickle cell disease. Federally-qualified health center is defined in section 1905(l)(2)(B) of the Social Security Act (42 U.S.C. 1396d(l)(2)(B)).

## What the grant funds

This notice announces the opportunity to apply for funding under the Sickle Cell Disease Treatment Demonstration Program (TDP). The purpose of the TDP is to increase access for individuals with sickle cell disease (SCD) to quality, coordinated, comprehensive care by: 1) increasing the number of clinicians or health professionals knowledgeable about the care of SCD, 2) improving the quality of care provided to individuals with SCD, and 3) improving care coordination with other providers.

## Questions people ask

### Is HRSA-21-032 still open?

No. It closed on May 3, 2021.

### Who can apply for Sickle Cell Disease Treatment Demonstration Program?

Health Resources and Services Administration accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Sickle Cell Disease Treatment Demonstration Program?

Closed May 3, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

About $5.0 million in total across about 5 awards.

### Who has won Sickle Cell Treatment Demonstration Program grants before?

The largest recipients over five fiscal years were University of Alabama at Birmingham, The Johns Hopkins University, The Washington University. The program made 5 awards worth $27.0 million in that time.